



August 14, 2024

Report to Shareholders for year end December 31, 2023

2023 saw a continuation of the strategy started in 2019 with the change to a lower cost model. We became increasingly virtual, working in home offices, although both the Scientific Director and Product Manager attended the SMASH NMR conference in Baveno, Italy in the Fall.

Software Sales increased in 2023, with a significant increase in perpetual license upgrades. The improvement in upgrade sales can be attributed to a significant improvement to the Chenomx NMR Suite Professional Version with a new COMPLETE Autofit Tool created by our Scientific Director, Pascal Mercier. Profits for 2023 increased significantly relative to the prior year. There was a small decrease in contract services for 2023 but we've seen a significant rebound in 2024.

There was one primary change to our salaries relative to subcontractor expenses, as Pascal Mercier was moved from a contract scientific advisor, to a full-time scientific director role with the company.

We welcome any comments from shareholders regarding these results.

A handwritten signature in blue ink, appearing to read 'Neil Taylor', written over a horizontal line.

Neil Taylor
President and CEO
Chenomx Inc.